Imfinzi

News

AZ eyes Q3 FDA decision for Imfinzi in biliary tract cancer

The FDA has kicked off a priority review of AstraZeneca's checkpoint inhibitor Imfinzi for biliary tract cancer (BTC), setting up what could be approval for an immunotherapy for the group o

News

AstraZeneca's Imfinzi fails in cervical cancer bid

AstraZeneca's hopes of developing its PD-L1 inhibitor Imfinzi for cervical cancer have been hit by a failed phase 3 trial of the drug alongside chemotherapy as a first-line treatment for wo

News

AZ's Imfinzi is first immunotherapy to raise survival in bil...

AstraZeneca's checkpoint inhibitor Imfinzi has become the first cancer immunotherapy to improve survival in previously-untreated patients with biliary tract cancer (BTC), a rare and aggress

News

AZ's COVID-19 jab sales top $1.2bn, but come at a loss

AstraZeneca said this morning that it has made $1.2 billion in sales from its COVID-19 vaccine Vaxzevria in the first half of this year, but making it available at no profit had weighed on

News

AstraZeneca bags Imfinzi okay in big Chinese lung cancer mar...

China has approved AstraZeneca's PD-1/PD-L1 inhibitor Imfinzi to treat small-cell lung cancer (SCLC), an aggressive form of the disease that accounts for around 15% of all lung cancer cases

News

AZ withdraws Imfinzi in US bladder cancer use after trial fa...

AstraZeneca has suffered a setback after it voluntarily withdrew its cancer immunotherapy Imfinzi (durvalumab) in a bladder cancer indication in the US.

AZ eyes Q3 FDA decision for Imfinzi in biliary tract cancer

AstraZeneca's Imfinzi fails in cervical cancer bid

AZ's Imfinzi is first immunotherapy to raise survival in bil...

AZ's COVID-19 jab sales top $1.2bn, but come at a loss

AstraZeneca bags Imfinzi okay in big Chinese lung cancer mar...

AZ withdraws Imfinzi in US bladder cancer use after trial fa...

GSK pursues $10.6bn takeover of cancer biotech Nuvalent

Discover a new era of healthcare panel engagement: Grounded ...

Imfinzi

Editor's Picks